



Tackling Antimicrobial Resistance in Neonatal Infections

Guest Editors:

Dr. Laura Folgori

Department of Paediatrics,
Vittore Buzzi Children Hospital,
University of Milan, Milan, Italy

Dr. Ilia Bresesti

Department of Woman and Child,
Filippo Del Ponte Hospital,
University of Insubria, Varese,
Italy

Dr. Lucia Barcellini

University of Milan, Department
of Paediatrics, Vittore Buzzi
Children Hospital, Milan, Italy

Deadline for manuscript
submissions:

closed (31 August 2023)

Message from the Guest Editors

With this Special Issue, as part of the scientific community, we aim to foster international research to deepen the role of the main determinants leading to adverse outcomes in newborns with SBI. Improved surveillance programs collecting neonatal AMR data and clinical outcomes are critical to allowing benchmarking and designing properly targeted interventions to decrease mortality. Future studies need to focus on improving mortality outcomes and defining the attributable burden of AMR in this population.

High-quality reviews and original studies are both welcome. We are particularly interested in the following topics:

- Epidemiology and impact of AMR in neonatal intensive care;
- Relationship between colonization and infections;
- Correlation between resistance and virulence factors/genes;
- Antimicrobial stewardship programs in neonatal settings;
- Outbreaks of MDR rods in NICU.



Keywords: infant, newborn; intensive care units; neonatal; bacteremia; drug resistance; microbial; virulence factors; mortality; antimicrobial stewardship; outbreaks



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)